Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.

11. november 2026 oppdatert av: Quanzhou First Hospital

A Randomized Controlled Study Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer (Including PRO and Health Economics Evaluation)

To compare the 12-month "treatment success" rate between a single SBRT dose of 30 Gy/1 and three SBRT doses totaling 54 Gy/3 in elderly or frail patients with early-stage NSCLC.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Study Design and Methods

  1. Study design and rationale. This study is a single-center, open-label, randomized 1:1, Simon-optimal two-stage screening Phase II trial employing a randomized controlled trial (RCT) design. Randomization was used rather than a single-arm design to enable comparison between the two fractionation regimens under concurrent control and to reduce selection bias; a two-stage screening design with early futility termination was adopted because the number of cases that a single center can accommodate is limited, necessitating the use of a minimal sample size to determine whether a single fraction achieves an acceptable treatment success rate. The study was open-label because radiotherapy cannot be blinded for either the patients or the treating physicians; however, local failure and toxicity grades were assessed by blinded, independent radiology/radiotherapy physicians who were not involved in the treatment, while PROs were patient self-reported and thus unaffected by blinding; health economic data were collected by an independent research assistant. The futility boundary was applied only to Arm A (single fraction), whereas Arm B continued to enroll patients as a concurrent standard-of-care control.

  2. Study population. Inclusion criteria: ① Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); or, in the absence of pathological confirmation, patients who simultaneously meet all of the following criteria: (a) Chest CT demonstrates peripheral solid nodules or masses with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant metastases or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with malignancy; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo biopsy due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and stage T1N0M0 (8th edition TNM, IA1-IA3); patients with invasion of the visceral pleura or atelectasis, classified as T2aN0M0 (IB), may also be included. ③ At enrollment, whether the diagnosis was "histologically/cytologically confirmed" was recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will withdraw from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or <75 years but meeting any one of the following criteria: CCI ≥3, ECOG 2-3, positive G8 screening, or CFS ≥4 on the Clinical Fatigue Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed informed consent. Exclusion criteria: ① central or supercentral tumors (single fraction is not applicable); ② prior history of thoracic radiotherapy; ③ active infection in the ipsilateral lung or mediastinum; ④ severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO <35% of predicted value); ⑤ patients requiring anticoagulation who cannot discontinue anticoagulation due to high bleeding risk; ⑥ other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ inability to complete the 12-month follow-up or the PRO questionnaire; ⑧ patients deemed unsuitable for enrollment by the investigator.

  3. Randomization and stratification. Allocation ratio: 1:1; method: centralized randomization and block randomization (with a specified block size); allocation sequences were generated by independent statisticians using R/Python; stratification factors: ① age (≥80 years vs. 75-79 years); ② ECOG score (0-1 vs. 2-3); ③ maximum tumor diameter (≤2 cm vs. 2-3 cm). Allocation was performed by research assistants who were not involved in clinical decision-making, using sealed envelopes or an electronic randomization system.

  4. Interventions. Arm A (experimental group): a single SBRT session at 30 Gy per session (BED10 = 120). Arm B (control group): three SBRT sessions at 54 Gy per session (BED10 = 151.2), administered once every other day (fixed treatment plan). Both arms utilized 4DCT-based respiratory motion management, IGRT/CBCT verification for each session, and FFF beam delivery; the technical modality could be either VMAT or a fixed field. The planning target volume was expanded according to the hospital's standard (ITV + 3-5 mm), as specified in the dosimetry documentation appendix.

  5. Organs at Risk (OARs) and Dose Limits. The following must be assessed and reported: cardiac substructures (left anterior descending artery [LAD], left atrium, sinoatrial node), proximal bronchial tree, chest wall, brachial plexus, esophagus, and major vessels. The limits shall be set according to the existing standards for single-fraction SBRT implemented at our institution and included as an appendix to the treatment plan; for the B-arm, the three-fraction standard shall apply. Quality assurance (QA) shall be performed in accordance with ICRU 91 and our institution's SBRT QA protocol; prior to the initiation of this project, a single-fraction dosimetric audit must be completed, and it is recommended that end-to-end verification be performed on the first 10 enrolled cases.

    Note: The specific values shall be subject to the appendix of the hospital's current SBRT dosimetry standards; this protocol does not pre-encode any limits that have not been approved by the hospital.

  6. Endpoint System. Primary endpoint: the 12-month "treatment success" composite endpoint, which requires the simultaneous fulfillment of the following criteria: (1) survival; (2) no local failure, assessed according to a pre-specified, uniquely defined imaging criteria (RECIST 1.1 + PET/CT metabolic response); and (3) no treatment-related grade ≥3 toxicity (CTCAE 5.0), with a follow-up window from randomization through 12 months. Secondary endpoints: efficacy (12-/24-month local control rate, PFS, OS, and distant failure rate); toxicity (grade ≥3 toxicity throughout the study, grade ≥2 cardiac events, grade ≥2 radiation pneumonitis, chest wall/rib fractures, and esophagitis); feasibility (treatment completion rate, regimen deviation rate, and treatment discontinuation rate); and functional outcomes (changes in FEV1 and DLCO from baseline to 12-/24 months). Exploratory endpoints: hematologic toxicity (the nadir of absolute lymphocyte count) and the generation of an immunoprotective SBRT hypothesis; the correlation between radiomics/doseomics and local failure.

  7. PRO Sub-study (Pretargeted). Instruments: EORTC QLQ-C30 (Chinese version), QLQ-LC13 (Chinese version), EQ-5D-5L (Chinese version, for utility values and QALY calculation), and a treatment burden diary card (number of treatment days, number of round trips, number of days with family care, and number of days of work absence). Assessment time points: baseline, treatment completion (±2 weeks), and 3, 6, 12, and 24 months. The primary PRO analysis metric is the change in the global health status (QL2 scale) of the 12-month QLQ-C30 from baseline. Statistical methods: a repeated-measures mixed-effects model (MMRM), with fixed effects including treatment group, time point, treatment × time point interaction, stratification factors, and baseline value; missing data handling follows the SISAQOL-IMI international guidelines; the handling rule for deaths is predefined (with a sensitivity analysis stating that "death is treated as the worst-case value"); scores are recorded according to the official EORTC scoring manual. Honesty statement: The PRO sub-study is positioned as a pretargeted secondary/exploratory analysis and is not intended for testing primary hypotheses; a separate power calculation was not performed based on the sample size planned in this protocol (77 per arm); if the 12-month difference in the QLQ-C30 were elevated to a shared primary endpoint (Δ=8 points, σ=20), approximately 99 cases per group, totaling 198 cases (including 218 cases after inflation), would be required, which would be unfeasible for a single center; therefore, PRO results are reported as effect sizes and 95% CIs, without stating "statistical power." The number of treatment days, number of round trips, and number of days of care are designed as deterministic intergroup differences (1 trip vs. 3 trips); they are not used for hypothesis testing but serve solely to quantify treatment burden and provide input parameters for the cost model.

  8. Health Economics Sub-study (Preliminary). Research Question: From the perspective of China's healthcare system and the social perspective, what is the incremental cost-effectiveness ratio (ICER) between a single SBRT session at 30 Gy/1 and three SBRT sessions at 54 Gy/3? Model: Decision analysis model (Markov or partitioned survival model), with a time horizon of 5 years and a cycle length of 1 month. Perspectives: ① China's healthcare system perspective; ② Social perspective (including indirect costs for patients and families). Outcome Measures: ① Incremental cost per case achieving "12-month treatment success"; ② Incremental cost per QALY gained (ICER, based on EQ-5D-5L utility values). Uncertainty Analysis: Single-factor sensitivity analysis + probabilistic sensitivity analysis (PSA, ≥1,000 Monte Carlo simulations, cost-effectiveness acceptability curve CEAC). The payment willingness threshold is set at 3 times the per capita GDP/QALY, following China's official convention (the threshold value is cited and incorporated using the latest official statistical data during analysis, without being pre-hardcoded); costs and outcomes are discounted annually (a 5% discount rate is recommended, citing the current version of China's pharmacoeconomic evaluation guidelines). Honesty Statement: A single fraction reduces the number of treatment sessions, but the machine utilization time for a single 30 Gy session may exceed that of each 18 Gy session; no prior assumption is made regarding a reduction in total cost; if 12-month survival is similar, the expected QALY gain is likely limited, and this possibility will be reported truthfully.

  9. Sample size and two-stage design. The design is based on the Simon optimal two-stage approach with a 1:1 randomization ratio. Parameters: H₀: H₁ = p₀ 0.72: p₁ 0.85; one-sided α = 0.05, power = 0.80. In the first stage, each arm will have 24 participants; if the number of successes ≤ 18, the arm will be terminated (declared ineffective); in the second stage, each arm will be expanded to 77 participants; if the number of successes ≥ 62, the trial will be deemed "promising." The planned total sample size is 77 participants per arm, totaling 154 participants; after applying a 10% inflation factor, this becomes 85 participants per arm, totaling 170 participants; based on the design expectations, approximately 80 participants will be enrolled (E[N] = 39.8 per arm). All figures are derived from the actual output of the scripts in the 04_samplesize_estimation directory (see row 3, category S3, of the Single-Center Protocol Sample Size.csv; Simon optimal p₀ = 0.72, p₁ = 0.85: n₁ = 24, r₁ = 18, n = 77, E[N] = 39.8); these are analytical estimates and contain no simulation data. Enrollment rate and timeline: A "progress review point" will be established after 12 months of enrollment; if the actual annual enrollment is <15 participants, the risk contingency plan will be activated (extend the enrollment period / add additional collaborative centers / adjust the lower age limit), without altering the primary endpoint or the two-stage structure.

  10. Key points of the Statistical Analysis Plan (SAP). Analysis sets: ITT (primary), mITT (at least one radiotherapy treatment received), PP, and safety set (at least one radiotherapy treatment received). Primary analyses: 12-month treatment success rate calculated by arm and its 95% exact binomial confidence interval; difference in rates between the two arms and its 95% CI; a prespecified non-formal two-arm superiority test will not be performed (Phase II screening design); Arm A will be compared against p₀ = 0.72 using the Simon rule, while the results for Arm B will be reported as contemporaneous controls. Time-to-event endpoints: Kaplan-Meier method + Cox proportional hazards model (HR and 95% CI reported); because non-tumor-related deaths are common in older populations, the competing-risk scenario must also include the Fine-Gray cumulative incidence function (with results for cause-specific and subdistribution analyses reported concurrently); the limitation that "sample-size estimation is based on a closed-form expression and does not account for competing risks" must be explicitly stated in the SAP. Safety: According to CTCAE 5.0 grading, report the number and proportion of adverse events at each grade, with comparisons made using Fisher's exact test. PROs: According to Section 3.7 (MMRM + SISAQOL-IMI). Health economics: According to Section 3.8 (decision model + PSA + CEAC). Interim analyses: Only for futility termination (Phase I); no early termination for efficacy superiority will be permitted to avoid α consumption. Multicentricity: the primary endpoint is reported as a single, unadjusted endpoint; all secondary/exploratory endpoints are labeled as exploratory and unadjusted.

Studietype

Intervensjonell

Registrering (Antatt)

170

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Wenjie Cai, MD
  • Telefonnummer: +8613805997393
  • E-post: cwj@qzdyyy.com

Studiesteder

    • Fujian
      • Quanzhou, Fujian, Kina, 362002
        • Quanzhou First Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:① Non-small cell lung cancer (NSCLC) confirmed by histology or cytology; or cases that have not yet undergone pathological confirmation but simultaneously meet all of the following criteria: (a) Chest CT demonstrates a peripheral solid nodule or mass with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant metastases or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with malignancy; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo biopsy due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and a stage of T1N0M0 (8th edition TNM, IA1-IA3); those with invasion of the visceral pleura or atelectasis classified as T2aN0M0 (IB) may also be eligible for inclusion. ③ At enrollment, whether the diagnosis was "histologically/cytologically confirmed" is recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will be withdrawn from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or age <75 years but meeting any of the following criteria: CCI ≥3, ECOG 2-3, positive G8 screening, or CFS ≥4 on the Clinical Frailty Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined surgery by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed informed consent Exclusion Criteria:① Central or supercentral tumors (single-dose fractionation is not applicable); ② Previous history of thoracic radiotherapy; ③ Active infection in the ipsilateral lung or mediastinum; ④ Severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO <35% of predicted value); ⑤ Patients requiring anticoagulation who cannot discontinue treatment due to a high risk of bleeding; ⑥ Presence of other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ Patients who are unable to complete the 12-month follow-up or the PRO questionnaire; ⑧ Patients deemed unsuitable for enrollment by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: test group

Single SBRT: 30 Gy / 1 session

single-session versus fractionated stereotactic radiotherapy

Aktiv komparator: control group

3 sessions of SBRT, 18 Gy per session

single-session versus fractionated stereotactic radiotherapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Overall Survival
Tidsramme: 12-month
12-month
Local Failure Free Survival
Tidsramme: 12-month
12-month

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Serious Adverse Event Free Survival
Tidsramme: 12-month

Number of participants with grade ≥3 treatment-related adverse events as assessed by CTCAE v4.0

12-month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

31. desember 2031

Studiet fullført (Antatt)

31. desember 2031

Datoer for studieregistrering

Først innsendt

4. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere